CoChat
Sign Up
Cited by 122Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsClinical practice guidelines implementation

The DOI matches its Crossref record; 752 of the 752 references it cites were found in a registry or an index.

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members, Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie, de Ferranti, Sarah D., Gianos, Eugenia, Gluckman, Ty J., Gradney, Kristen F., Isiadinso, Ijeoma, Lloyd-Jones, Donald M., Marrs, Joel C., Martin, Seth S., McLain, Kellie H., Mehta, Laxmi S., Mora, Samia, Mulugeta, Wudeneh M., Natarajan, Pradeep, Navar, Ann Marie, Orringer, Carl E., Polonsky, Tamar S., Reynolds, Harmony R., Saseen, Joseph J., Shapiro, Michael D., Soffer, Daniel E., Tynes, Sheila A., Villavaso, Chloé D., Virani, Salim S., Wilkins, John T., Rohatgi, Anand, Kim, Samuel M., Alexander, Karen P., Anderson, Cheryl, Benziger, Catherine P., Dixon, Dave L., Duprez, Daniel, Ferdinand, Keith C., Goldberg, Anne Carol, Joshi, Parag, Knowles, Joshua W., Lavie Jr, Carl (Chip) J., Linderbaum, Jane A., McEvoy, John William, Mehta, Anurag, Merz, C. Noel Bairey, Nambi, Vijay, Orkaby, Ariela R., Peña,, Jessica M., Rosenson, Robert, Ruisinger, Janelle, Sandner, Sigrid E., Schott, Stacey L., Sperling, Laurence (Larry), Stone, Neil J., Toth, Peter, Ware, Adam L., Whelton, Seamus Paul, Young, James·2026·Circulation
DOI 10.1161/cir.0000000000001423
Open this paper in CoChat — free account

Abstract

AIM: The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000001423

Cites

752 of 752 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 752 references

Research works printed but not linked: 243

  1. Kazi DS, Abdullah AR, Arnold SV, et al. 2025 AHA/ACC statement on cost/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e332–e358.
  2. Otto CM, Abdullah AR, Davis LL, et al. 2025 ACC/AHA guideline core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152:e359–e370.
  3. Jneid H, Abdullah AR, Ferrari V, et al. Guidance for incorporating FDA processes into the ACC/AHA clinical practice guideline methodology: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152:e323–e331.
  4. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11):CD006401.
  5. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213–S256.
  6. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths-United States, 1999-2006. MMWR Morb Mortal Wkly Rep. 2010;59:29–33.
  7. 10.1016/S0140-6736(19)32519-X · DOI
  8. 10.1161/CIR.0000000000000625 · DOI · Paper page
  9. 10.1161/CIRCULATIONAHA.119.041149 · DOI · Paper page
  10. MacDougall DE, Tybjaerg-Hansen A, Knowles JW, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Eur Heart J. 2025;ehaf297.
  11. 10.1056/NEJMoa1812792 · DOI · Paper page
  12. 10.1056/NEJMoa1615664 · DOI · Paper page
  13. 10.1056/NEJMoa2215024 · DOI · Paper page
  14. 10.1161/CIR.0000000000001078 · DOI · Paper page
  15. 10.1161/CIR.0000000000000678 · DOI · Paper page
  16. 10.1056/NEJMoa2109191 · DOI
  17. 10.1056/NEJMoa1800389 · DOI · Paper page
  18. 10.1161/CIR.0000000000000678 · DOI · Paper page
  19. 10.1161/CIR.0000000000000625 · DOI · Paper page
  20. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  21. 10.1210/clinem/dgaa673 · DOI · Paper page
  22. 10.1093/eurheartj/ehad211 · DOI
  23. 10.1161/CIR.0000000000000678 · DOI · Paper page
  24. 10.1111/j.1467-789X.2012.01021.x · DOI · Paper page
  25. 10.1016/j.jacl.2023.05.099 · DOI
  26. 10.1093/ajcn/56.2.320 · DOI · Paper page
  27. 10.1161/CIR.0000000000001078 · DOI · Paper page
  28. 10.1007/s40279-024-02115-z · DOI · Paper page
  29. 10.1056/NEJMoa020194 · DOI · Paper page
  30. Li Y, Zhai Q, Li G, et al. Effects of different aerobic exercises on blood lipid levels in middle-aged and elderly people: a systematic review and bayesian network meta-analysis based on randomized controlled trials. Healthcare (Basel). 2024;12:1309.
  31. 10.1161/CIR.0b013e3182160726 · DOI · Paper page
  32. US Department of Health and Human Services. Physical Activity Guidelines for Americans. 2nd edition. US Department of Health and Human Services; 2018.
  33. 10.1056/NEJMoa1410489 · DOI · Paper page
  34. 10.1056/NEJMoa1615664 · DOI · Paper page
  35. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  36. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  37. 10.1016/j.jacl.2023.05.099 · DOI
  38. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  39. 10.1056/NEJMoa1812792 · DOI · Paper page
  40. 10.1016/j.jacc.2022.07.006 · DOI · Paper page
  41. 10.1161/CIR.0000000000000709 · DOI · Paper page
  42. 10.1161/CIR.0000000000000625 · DOI · Paper page
  43. 10.1161/CIR.0000000000000456 · DOI
  44. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
  45. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  46. 10.1016/j.jacc.2022.07.006 · DOI · Paper page
  47. 10.1056/NEJMoa1410489 · DOI · Paper page
  48. 10.1056/NEJMoa1615664 · DOI · Paper page
  49. 10.1056/NEJMoa1801174 · DOI · Paper page
  50. 10.1016/j.atherosclerosis.2018.06.002 · DOI · Paper page
  51. 10.1161/JAHA.118.011662 · DOI · Paper page
  52. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  53. 10.1016/j.jacc.2020.07.059 · DOI · Paper page
  54. 10.1161/circulationaha.114.012477 · DOI
  55. Zheutlin AR, Handoo F, Luebbe S, et al. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Eur Heart J. 2025;eha472.
  56. 10.1056/NEJMoa2109191 · DOI
  57. 10.1001/jamacardio.2021.3508 · DOI · Paper page
  58. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.
  59. 10.1161/CIR.0000000000000625 · DOI · Paper page
  60. 10.1161/CIRCULATIONAHA.123.067626 · DOI · Paper page
  61. 10.1016/S0140-6736(12)60367-5 · DOI · Paper page
  62. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  63. 10.1161/CIR.0000000000000625 · DOI · Paper page
  64. 10.1161/CIR.0000000000000678 · DOI · Paper page
  65. 10.1161/ATVBAHA.120.315291 · DOI · Paper page
  66. 10.1056/NEJMoa0807646 · DOI · Paper page
  67. 10.1056/NEJMoa1107477 · DOI · Paper page
  68. 10.1161/CIR.0000000000000625 · DOI · Paper page
  69. 10.1161/CIR.0000000000000678 · DOI · Paper page
  70. Urbut SM, Cho SMJ, Paruchuri K, et al. Dynamic importance of genomic and clinical risk for coronary artery disease over the life course. Circ Genom Precis Med. 2023;18:e004681.
  71. 10.1001/jama.2025.0584 · DOI
  72. 10.1093/eurheartj/ehad211 · DOI
  73. 10.1007/s40279-024-02115-z · DOI · Paper page
  74. 10.1210/clinem/dgaa673 · DOI · Paper page
  75. 10.1016/S0140-6736(12)60367-5 · DOI · Paper page
  76. 10.1016/j.jacc.2020.07.059 · DOI · Paper page
  77. 10.1056/NEJMoa0807646 · DOI · Paper page
  78. 10.1056/NEJMoa1600176 · DOI · Paper page
  79. 10.1001/jama.279.20.1615 · DOI · Paper page
  80. 10.1001/jamacardio.2021.3508 · DOI · Paper page
  81. 10.1001/jama.2016.13985 · DOI · Paper page
  82. 10.1056/NEJMoa2215024 · DOI · Paper page
  83. 10.1161/CIR.0000000000000678 · DOI · Paper page
  84. 10.1161/circulationaha.114.012477 · DOI
  85. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  86. 10.1161/CIR.0000000000000625 · DOI · Paper page
  87. 10.7326/M16-0946 · DOI
  88. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  89. 10.1161/CIRCULATIONAHA.123.064168 · DOI
  90. 10.1161/circulationaha.116.022335 · DOI
  91. 10.1016/j.jacc.2016.03.520 · DOI · Paper page
  92. 10.1161/CIRCULATIONAHA.123.064168 · DOI
  93. 10.1056/NEJM199511163332001 · DOI · Paper page
  94. 10.1016/j.jacc.2016.03.520 · DOI · Paper page
  95. 10.1161/CIRCULATIONAHA.116.024541 · DOI
  96. 10.1056/NEJMoa1410489 · DOI · Paper page
  97. 10.1056/NEJMoa2215024 · DOI · Paper page
  98. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996–3003.
  99. Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2023;354–362.
  100. 10.1001/jama.2016.13985 · DOI · Paper page
  101. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  102. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  103. 10.1016/S0140-6736(14)61374-X · DOI
  104. 10.1056/NEJMoa2215024 · DOI · Paper page
  105. 10.1001/jama.2016.13985 · DOI · Paper page
  106. 10.1056/NEJM199511163332001 · DOI · Paper page
  107. 10.1161/CIRCULATIONAHA.117.027966 · DOI · Paper page
  108. 10.1136/bmj.a2423 · DOI
  109. 10.1016/j.jacc.2016.04.054 · DOI
  110. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  111. 10.1161/CIRCULATIONAHA.122.063460 · DOI · Paper page
  112. 10.1056/NEJMoa1410489 · DOI · Paper page
  113. 10.1056/NEJMoa1812792 · DOI · Paper page
  114. 10.1001/jama.2016.13985 · DOI · Paper page
  115. 10.1056/NEJMoa0807646 · DOI · Paper page
  116. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  117. 10.1056/NEJMoa2215024 · DOI · Paper page
  118. 10.1001/jama.2023.9696 · DOI · Paper page
  119. 10.1056/NEJMoa1615664 · DOI · Paper page
  120. 10.1056/NEJMoa1801174 · DOI · Paper page
  121. 10.1161/CIR.0000000000000625 · DOI · Paper page
  122. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  123. 10.1001/jama.2016.13985 · DOI · Paper page
  124. 10.1056/NEJMoa1410489 · DOI · Paper page
  125. 10.1056/NEJMoa2215024 · DOI · Paper page
  126. 10.1056/NEJMoa1801174 · DOI · Paper page
  127. 10.1056/NEJMoa1615664 · DOI · Paper page
  128. 10.1161/CIRCULATIONAHA.122.061620 · DOI · Paper page
  129. 10.1161/CIR.0000000000000625 · DOI · Paper page
  130. 10.1161/JAHA.122.029216 · DOI · Paper page
  131. 10.1016/j.jacc.2020.07.059 · DOI · Paper page
  132. 10.1056/NEJMoa1801174 · DOI · Paper page
  133. 10.1177/2047487319864671 · DOI · Paper page
  134. 10.1016/j.jcmg.2019.02.005 · DOI · Paper page
  135. 10.1016/j.jcmg.2023.03.008 · DOI
  136. 10.1093/eurheartj/ehy217 · DOI · Paper page
  137. 10.1001/jama.2025.0584 · DOI
  138. 10.1016/j.jacc.2018.09.051 · DOI
  139. 10.1001/jamacardio.2016.5493 · DOI
  140. 10.1016/j.jcct.2023.10.001 · DOI
  141. 10.1148/radiol.15142062 · DOI · Paper page
  142. 10.1161/CIRCULATIONAHA.122.062746 · DOI · Paper page
  143. 10.1016/j.jacl.2020.12.005 · DOI
  144. 10.1056/NEJMoa2215024 · DOI · Paper page
  145. Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373:1476–1477.
  146. 10.1056/NEJMoa1615664 · DOI · Paper page
  147. 10.1056/NEJMoa1801174 · DOI · Paper page
  148. 10.1161/circulationaha.116.027034 · DOI
  149. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  150. 10.1161/CIRCIMAGING.120.011701 · DOI
  151. 10.1001/jamacardio.2024.5702 · DOI
  152. 10.1093/ehjci/jex239 · DOI · Paper page
  153. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11):CD006401.
  154. 10.1056/NEJMoa1816454 · DOI
  155. 10.1126/science.aaf7000 · DOI · Paper page
  156. Schmieder RS, Krefting J, Ates S, et al. Clinical scores fail to sufficiently identify children with familial hypercholesterolemia. Eur J Prev Cardiol. 2025;zwaf301.
  157. 10.1001/jama.2019.4984 · DOI
  158. 10.1001/jamapediatrics.2021.2046 · DOI
  159. 10.1161/CIRCULATIONAHA.119.044795 · DOI
  160. 10.1016/j.jacc.2015.02.020 · DOI · Paper page
  161. 10.1056/NEJMoa2109191 · DOI
  162. 10.1001/jama.2023.8867 · DOI
  163. 10.1056/NEJMoa1602777 · DOI
  164. 10.1161/CIR.0000000000000625 · DOI · Paper page
  165. 10.1161/circulationaha.114.012477 · DOI
  166. 10.1016/j.jacc.2020.07.059 · DOI · Paper page
  167. 10.1056/NEJMoa2109191 · DOI
  168. 10.1161/circulationaha.116.022335 · DOI
  169. 10.1001/jamacardio.2021.3508 · DOI · Paper page
  170. 10.1001/jamanetworkopen.2021.36802 · DOI
  171. 10.1001/jamainternmed.2015.0289 · DOI · Paper page
  172. 10.1016/j.jacc.2016.05.084 · DOI
  173. 10.1161/CIR.0000000000001191 · DOI · Paper page
  174. Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;25:e41–e660.
  175. 10.1161/CIR.0000000000000625 · DOI · Paper page
  176. 10.1161/CIR.0000000000000678 · DOI · Paper page
  177. Dudum R, Huang Q, Yan XS, et al. Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels. J am Coll Cardiol Adv. 2024;3:100940.
  178. 10.1056/NEJMoa0706201 · DOI · Paper page
  179. 10.1016/S0140-6736(08)61240-4 · DOI · Paper page
  180. 10.1161/CIR.0000000000000625 · DOI · Paper page
  181. 10.1002/ejhf.247 · DOI · Paper page
  182. 10.1016/S0140-6736(11)60739-3 · DOI · Paper page
  183. Tunnicliffe DJ, Palmer SC, Cashmore BA, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023;2023:.
  184. Igweonu-Nwakile EO, Ali S, Paul S, et al. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus. 2022;14:e29140.
  185. 10.1016/j.jacc.2022.07.006 · DOI · Paper page
  186. 10.1001/jamainternmed.2013.3728 · DOI
  187. 10.1161/CIR.0000000000000456 · DOI
  188. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Accessed August 24 2025. https://www.ncbi.nlm.nih.gov/sites/books/NBK586306/.
  189. Sarkar S, Brown TT. Lipid disorders in people with HIV. Table 5. Interaction of antiretroviral therapy and statins. In: Feingold KR, Ahmed SF, Anawalt B, et al, editors. Endotext. MDText.com, Inc.; 2000. Accessed November 21, 2025. https://www.ncbi.nlm.nih.gov/books/NBK567198/table/lipid_hiv.T.interaction_of_antiretrovira.
  190. 10.1001/jamainternmed.2020.6084 · DOI · Paper page
  191. 10.1001/jamainternmed.2015.0289 · DOI · Paper page
  192. 10.1093/ajcn/56.2.320 · DOI · Paper page
  193. 10.1210/clinem/dgaa673 · DOI · Paper page
  194. 10.1056/NEJMoa1615664 · DOI · Paper page
  195. 10.1056/NEJMoa1801174 · DOI · Paper page
  196. 10.1056/NEJMoa2215024 · DOI · Paper page
  197. 10.1056/NEJMoa1812792 · DOI · Paper page
  198. 10.1161/CIRCULATIONAHA.123.067626 · DOI · Paper page
  199. 10.1016/j.jacc.2021.06.011 · DOI · Paper page
  200. 10.1016/j.jacl.2024.08.013 · DOI · Paper page

200 of 243 shown

Cited by

Sorted by citations

See all 122

Related

See all

Metadata

Authors
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., Mora, S., Mulugeta, W. M., Natarajan, P., Navar, A. M., Orringer, C. E., Polonsky, T. S., Reynolds, H. R., Saseen, J. J., Shapiro, M. D., Soffer, D. E., Tynes, S. A., Villavaso, C. D., Virani, S. S., Wilkins, J. T., Rohatgi, A., Kim, S. M., Alexander, K. P., Anderson, C., Benziger, C. P., Dixon, D. L., Duprez, D., Ferdinand, K. C., Goldberg, A. C., Joshi, P., Knowles, J. W., Lavie Jr, C. (. J., Linderbaum, J. A., McEvoy, J. W., Mehta, A., Merz, C. N. B., Nambi, V., Orkaby, A. R., Peña, Rosenson, R., Ruisinger, J., Sandner, S. E., Schott, S. L., Sperling, L. (., Stone, N. J., Toth, P., Ware, A. L., Whelton, S. P., & Young, J.
Affiliations
  • American Hospital Association (US)
  • Former ACC/AHA Joint Committee on Clinical Practice Guidelines member; current member during the writing effort.
  • American Geriatrics Society (US)
  • American Association of Cardiovascular and Pulmonary Rehabilitation representative.
  • ACC/AHA Task Force on Performance Measures liaison.
  • Patient representative.
  • Association of Black Cardiologists (US)
  • American Pharmacists Association (US)
  • American College of Preventive Medicine (US)
  • National Lipid Association (US)
  • American Society for Preventive Cardiology representative.
  • AHA/ACC Guidelines Staff Consultant.
  • Preventive Cardiovascular Nurses Association representative.
  • American Diabetes Association (US)
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2026-04-28
Volume
153
Issue
17
Pages
e1154-e1276
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/cir.0000000000001423
OpenAlex
W7135196205
Cited by
122
References
752
Citations by year
2026: 122
FWCI
769.87
Type
journal article
Language
en
Update notices
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords
dyslipidemia, dyslipidemia management, hypercholesterolemia, hypertriglyceridemia, serum cholesterol, lipid-lowering therapy, cardiovascular risk, lipid monitoring
MeSH terms
American Heart Association, Hypolipidemic Agents, Cardiology, Humans, United States, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review